Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 3
2009 4
2010 1
2011 3
2012 4
2013 3
2014 4
2015 3
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Bertagnolli MM, et al. J Clin Oncol. 2011 Aug 10;29(23):3153-62. doi: 10.1200/JCO.2010.33.0092. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747089 Free PMC article. Clinical Trial.
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group. Graziano SL, et al. J Thorac Oncol. 2010 Jun;5(6):810-7. doi: 10.1097/jto.0b013e3181d89f95. J Thorac Oncol. 2010. PMID: 20521348 Free PMC article. Clinical Trial.
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RA. Voorhees PM, et al. Br J Haematol. 2015 Nov;171(3):373-7. doi: 10.1111/bjh.13592. Epub 2015 Jul 22. Br J Haematol. 2015. PMID: 26202857 Free PMC article. Clinical Trial.
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Ogino S, et al. Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6. Clin Cancer Res. 2012. PMID: 22147942 Free PMC article. Clinical Trial.
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Lilenbaum R, Samuels M, Wang X, Kong FM, Jänne PA, Masters G, Katragadda S, Hodgson L, Bogart J, Bradley J, Vokes E. Lilenbaum R, et al. J Thorac Oncol. 2015 Jan;10(1):143-7. doi: 10.1097/JTO.0000000000000347. J Thorac Oncol. 2015. PMID: 25384173 Free PMC article. Clinical Trial.
24 results